The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase 1 study of MEDI3902, an investigational anti–Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults
Abstract
OBJECTIVES: MEDI3902 is a bivalent, bispecific human immunoglobulin G1κ monoclonal antibody that binds to both the Pseudomonas aeruginosa PcrV protein involved in host cell cytotoxicity and the Psl exopolysaccharide involved in P. aeruginosa colonization and tissue adherence. MEDI3902 is being developed for the prevention of nosocomial P. aeruginosa pneumonia in high-risk patients. METHODS: This phase 1 dose-escalation study (NCT02255760) evaluated the safety, pharmacokinetics, antidrug antibody (ADA) responses and ex vivo anticytotoxicity and opsonophagocytic killing activities of MEDI3902 after a single intravenous infusion in healthy adults aged 18 to 60 years. Fifty-six subjects were randomized in a 3:1 ratio to receive 250, 750, 1500 or 3000 mg of MEDI3902 or placebo and followed for 60 days afterwards. RESULTS: Treatment-emergent adverse events (TEAEs) were mild or moderate in severity; no serious TEAEs were observed. The most common TEAEs were infusion-related reactions. MEDI3902 exhibited approximately linear pharmacokinetics across the 250, 750 and 1500 mg doses and nonlinear pharmacokinetics between the 1500 and 3000 mg doses. One subject in the 3000 mg group tested positive for ADA on day 61 and had a lower MEDI3902 serum concentration from days 43 to 61 than ADA-negative subjects. Serum anticytotoxicity antibody concentrations and opsonophagocytic killing activity were correlated with MEDI3902 serum concentrations across all doses. CONCLUSIONS: Phase 1 study results of MEDI3902 in healthy subjects support further evaluation of its safety and efficacy in subjects at risk for P. aeruginosa pneumonia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These functions shift treatment from antibiotic killing alone to immune-enabled biofilm control, supported by clinical-stage antibodies and next-generation vaccine candidates [221,222].”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [221]
In the citing paper
“Broad target conservation supports clinical applicability [221,222,223].”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [221]
In the citing paper
“Phase one studies show favorable safety and pharmacokinetics (PKs) in healthy adults, and preclinical models show protection in bacteremia and pneumonia.”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [221]
In the citing paper
“The bispecific monoclonal antibody MEDI3902, also known as gremubamab, targets Psl and the type three secretion protein PcrV.”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [221]
In the citing paper
“Host-directed therapies counter adhesins and secretion systems, generate protective antibodies, and weaken the matrix.”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [221]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jones, R. N. (2010) · Clinical Infectious Diseases · doi:10.1086/653053 · Cited by 716
Research works printed but not linked: 17
- Esperatti, 2010, Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients, Am J Respir Crit Care Med, 182, 1533, 10.1164/rccm.201001-0094OC · DOI · Paper page
- Kyaw, 2015, Healthcare utilization and costs associated with S. aureus and P. aeruginosa pneumonia in the intensive care unit: a retrospective observational cohort study in a US claims database, BMC Health Serv Res, 15, 241, 10.1186/s12913-015-0917-x · DOI
- Desoubeaux, 2013, Therapeutic antibodies and infectious diseases, Tours, France, November 20–22, 2012, MAbs, 5, 626, 10.4161/mabs.25300 · DOI
- Desoubeaux, 2016, Therapeutic monoclonal antibodies for respiratory diseases: current challenges and perspectives, March 31–April 1, 2016, Tours, France, MAbs, 8, 999, 10.1080/19420862.2016.1196521 · DOI
- Hauser, 2009, The type III secretion system of Pseudomonas aeruginosa: infection by injection, Nat Rev Microbiol, 7, 654, 10.1038/nrmicro2199 · DOI · Paper page
- Sato, 2011, Multi-functional characteristics of the Pseudomonas aeruginosa type III needle-tip protein, PcrV; comparison to orthologs in other gram-negative bacteria, Front Microbiol, 2, 142, 10.3389/fmicb.2011.00142 · doi:10.3389/fmicb.2011.00142
- Sawa, 1999, Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury, Nat Med, 5, 392, 10.1038/7391 · DOI · Paper page
- Hattemer, 2013, Bacterial and clinical characteristics of health care– and community-acquired bloodstream infections due to Pseudomonas aeruginosa, Antimicrob Agents Chemother, 57, 3969, 10.1128/AAC.02467-12 · DOI
- Jackson, 2004, Identification of psl, a locus encoding a potential exopolysaccharide that is essential for Pseudomonas aeruginosa PA01 biofilm formation, J Bacteriol, 186, 4466, 10.1128/JB.186.14.4466-4475.2004 · DOI · Paper page
- Ma, 2009, Assembly and development of the Pseudomonas aeruginosa biofilm matrix, PLoS Pathog, 5, e1000354, 10.1371/journal.ppat.1000354 · DOI · Paper page
- Ryder, 2007, Role of polysaccharides in Pseudomonas aeruginosa biofilm development, Curr Opin Microbiol, 10, 644, 10.1016/j.mib.2007.09.010 · DOI · Paper page
- DiGiandomenico, 2012, Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening, J Exp Med, 209, 1273, 10.1084/jem.20120033 · DOI · Paper page
- DiGiandomenico, 2014, A multifunctional bispecific antibody protects against Pseudomonas aeruginosa, Sci Transl Med, 6, 10.1126/scitranslmed.3009655 · DOI · Paper page
- Warrener, 2014, A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models, Antimicrob Agents Chemother, 58, 4384, 10.1128/AAC.02643-14 · DOI
- DiGiandomenico, 2004, Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model, Infect Immun, 72, 7012, 10.1128/IAI.72.12.7012-7021.2004 · doi:10.1128/iai.72.12.7012-7021.2004
- Kunz, 2010, Emerging resistant Gram-negative aerobic bacilli in hospital-acquired infections, Chemotherapy, 56, 492, 10.1159/000321018 · DOI
- Thaden, 2016, Pseudomonas aeruginosa bacteremic patients exhibit nonprotective antibody titers against therapeutic antibody targets PcrV and Psl exopolysaccharide, J Infect Dis, 213, 640, 10.1093/infdis/jiv436 · DOI
Cited by
Antimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
Horcajada, J. P., Montero, M., Oliver, A., Sorlí, L., Luque, S., Gómez-Zorrilla, S., Benito, N., & Grau, S. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00031-19 · Cited by 961
Liao, C., Huang, X., Wang, Q., Yao, D., & Lu, W. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.926758 · Cited by 309
Bispecific Antibodies: From Research to Clinical Application
Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., & Qian, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626616 · Cited by 305
Alternative therapeutic strategies to treat antibiotic-resistant pathogens
MacNair, C. R., Rutherford, S. T., & Tan, M.-W. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00993-0 · Cited by 276
Metadata
- Authors
- Ali, S. O., Yu, X. Q., Robbie, G. J., Wu, Y., Shoemaker, K., Yu, L., DiGiandomenico, A., Keller, A. E., Anude, C., Hernandez-Illas, M., Bellamy, T., Falloon, J., Dubovsky, F., & Jafri, H. S.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 25
- Issue
- 5
- Pages
- 629.e1-629.e6
- ISSN
- 1198-743X
- Cited by
- 124
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- MedImmune
- global biologics R&D arm of AstraZeneca
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.